---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-048719"
form_type: "8-K"
ticker: "A"
cik: "0001090872"
company_name: "AGILENT TECHNOLOGIES, INC."
filed_at: "2021-09-23T23:59:59+00:00"
generated_at: "2026-06-29T01:42:35.750084+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Agilent appoints Pfizer CSO Mikael Dolsten to board effective Sept. 21

## Summary
- Dr. Mikael Dolsten, Pfizer CSO & President of Worldwide R&D and Medical, joins Agilent board.
- He co-led Pfizer's collaboration with BioNTech on COMIRNATY (COVID-19 vaccine).
- Dolsten brings 30+ years pharma experience and involvement in 30+ drug/vaccine approvals.
- He will serve on Audit & Finance and Nominating/Corporate Governance committees.
- Board size increased from 10 to 11; Dolsten stands for re-election at 2022 annual meeting.

## SEC filing metadata
- accession: 0001564590-21-048719
- form_type: 8-K
- ticker: A
- cik: 0001090872
- company_name: AGILENT TECHNOLOGIES, INC.
- filed_at: 2021-09-23T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1090872/000156459021048719/0001564590-21-048719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1090872/000156459021048719/a-8k_20210921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-048719
- JSON: https://secwatch.observer/filing/0001564590-21-048719.json
- Plain text: https://secwatch.observer/filing/0001564590-21-048719.txt

## Key facts
- Executive change
  Mikael Dolsten was appointed as Director at AGILENT TECHNOLOGIES, INC..
  - Action: appointed
  - Role: Director
  source text: appointed Dr. Mikael Dolsten to fill the vacancy so created, both effective September 21, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1090872/000156459021048719/0001564590-21-048719-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.